Compare XRAY & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | WVE |
|---|---|---|
| Founded | 1899 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | XRAY | WVE |
|---|---|---|
| Price | $12.46 | $12.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $13.80 | ★ $30.44 |
| AVG Volume (30 Days) | ★ 4.4M | 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.67 | $16.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $5.28 |
| 52 Week High | $19.27 | $21.73 |
| Indicator | XRAY | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 41.52 |
| Support Level | $12.70 | $12.51 |
| Resistance Level | $14.18 | $14.15 |
| Average True Range (ATR) | 0.57 | 0.75 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 27.97 | 10.24 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.